A major breakthrough in ovarian cancer treatment is now available on the NHS, offering new hope to hundreds of women each year. The drug, often described as a 'biological missile' or 'Trojan horse' therapy, delivers chemotherapy directly to cancer cells while largely sparing healthy tissue, reducing many of the debilitating side effects associated with conventional treatment. Clinical trials showed the drug extends average survival from 12.8 months to 16.5 months for eligible patients and significantly improves quality of life. Women receiving the treatment often experience less fatigue and sickness, require fewer hospital visits, and are more likely to retain their hair. Patients have described the therapy as life-changing, enabling them to enjoy family time, travel, and everyday activities once again. Cancer specialists and charities have welcomed the NHS decision, describing it as the most important development in treating this form of ovarian cancer for two decades.